1. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer

   • Fausto Petrelli
   • Sandro Barni

   Review 01 November 2013 Pages: 227 - 235

   

2. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes

   • Aleix Prat
   • Olga Karginova
   • Charles M. Perou

   Preclinical Study Open access 27 October 2013 Pages: 237 - 255

   

3. Genomic profiling of histological special types of breast cancer

   • Hugo M. Horlings
   • Britta Weigelt
   • Jorge S. Reis-Filho

   Preclinical study 27 October 2013 Pages: 257 - 269

   

4. Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling

   • Reginald M. Gorczynski
   • Zhiqi Chen
   • Kai Yu

   Preclinical study Open access 29 October 2013 Pages: 271 - 282

   

5. Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue

   • Myriam Vilasco
   • Laudine Communal
   • BRACAPS

   Preclinical Study 29 October 2013 Pages: 283 - 296

   

6. RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial–mesenchymal transition

   • Chonggao Yin
   • Hongli Li
   • Weiyi Chen

   Preclinical Study 01 November 2013 Pages: 297 - 309

   

7. Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers

   • Julia Y. S. Tsang
   • Ying Kin Kwok
   • Gary M. Tse

   Preclinical study 02 November 2013 Pages: 311 - 322

   

8. The prognostic value of apoptotic and proliferative markers in breast cancer

   • Charla C. Engels
   • Francesca Ruberta
   • Peter J. K. Kuppen

   Preclinical Study 06 November 2013 Pages: 323 - 339

   

9. Upregulated WAVE3 expression is essential for TGF-β-mediated EMT and metastasis of triple-negative breast cancer cells

   • Molly A. Taylor
   • Gangarao Davuluri
   • Khalid Sossey-Alaoui

   Preclinical study 07 November 2013 Pages: 341 - 353

   

10. Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients

    • Esther M. de Kruijf
    • Charla C. Engels
    • Peter J. K. Kuppen

    Preclinical study 07 November 2013 Pages: 355 - 364

    

11. Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns

    • Sabrina A. Bardowell
    • Joel Parker
    • Theresa Swift-Scanlan

    Preclinical Study Open access 10 November 2013 Pages: 365 - 380

    

12. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients

    • John W. Smith II
    • Svetislava Vukelja
    • Joyce O’Shaughnessy

    Clinical Trial 29 October 2013 Pages: 381 - 388

    

13. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk

    • Shaveta Vinayak
    • Erich J. Schwartz
    • Allison W. Kurian

    Clinical Trial 29 October 2013 Pages: 389 - 398

    

14. Ultrasonic dissection system technology in breast cancer: a case–control study in a large cohort of patients requiring axillary dissection

    • F. Lumachi
    • S. M. M. Basso
    • G. B. Chiara

    Clinical trial 02 November 2013 Pages: 399 - 404

15. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases

    • Nancy U. Lin
    • Rachel A. Freedman
    • Eric P. Winer

    Clinical trial 07 November 2013 Pages: 405 - 414

    

16. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

    • Kalliopi P. Siziopikou
    • Stewart J. Anderson
    • Norman Wolmark

    Clinical trial 08 November 2013 Pages: 415 - 421

    

17. Barriers to physical activity and healthy eating in young breast cancer survivors: modifiable risk factors and associations with body mass index

    • Emily E. Ventura
    • Patricia A. Ganz
    • Catherine M. Crespi

    Epidemiology 01 November 2013 Pages: 423 - 433

    

18. Aromatase inhibitor therapy and hair loss among breast cancer survivors

    • Lisa Gallicchio
    • Carla Calhoun
    • Kathy J. Helzlsouer

    Epidemiology 07 November 2013 Pages: 435 - 443

19. Is there a role for routine screening MRI in women with LCIS?

    • Tari A. King
    • Shirin Muhsen
    • Monica Morrow

    Brief Report 19 October 2013 Pages: 445 - 453

    

20. Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93

    • Olivia Pagani
    • Shari Gelber
    • Edda Simoncini

    Brief Report 07 November 2013 Pages: 455 - 459

    

21. Closing an on-going clinical trial: when is it betrayal of participants?

    • Cynthia Chauhan
    • Mary Lou Smith

    Letter to the Editor Open access 26 October 2013 Pages: 461 - 462

22. Margin negative, breast conserving resection: adequate for benign phyllodes tumors, but inadequate therapy for borderline and malignant phyllodes tumors

    • Richard J. Barth Jr.

    Invited Commentary 01 November 2013 Pages: 463 - 464